Table of Contents
Volume 100, Issue 8: August 2015

Cover Figure

Celebration of volume 100
(image created by www.somersault1824.com)

Editorials

989  Precision medicine in diffuse large B-cell lymphoma: hitting the target
     Joost S. Vermaat, et al.

994  Oxidative stress as a therapeutic perspective for ATM-deficient chronic lymphocytic leukemia patients
     Veronika Navrkalova, et al.

Guideline Article

997  Consensus recommendations for the diagnosis and management of hemophagocytic lymphohistiocytosis associated with malignancies
     Kai Lehmberg, et al.

Articles

Hematopoiesis

1005 TIMP-1 signaling via CD63 triggers granulopoiesis and neutrophilia in mice
     Julia Kobuch, et al.

1014 Chronic exposure to IFNα drives medullar lymphopoiesis towards T-cell differentiation in mice
     Marianna Di Scala, et al.

Red Cell Biology & Its Disorders

1023 Deficiency in mouse hyaluronidase 2: a new mechanism of chronic thrombotic microangiopathy
     Cécile Onclinx, et al.

Coagulation & Its Disorders

1031 The international, prospective Glanzmann Thrombasthenia Registry: treatment modalities and outcomes of non-surgical bleeding episodes in patients with Glanzmann thrombasthenia
     Giovanni Di Minno, et al.

1038 The international, prospective Glanzmann Thrombasthenia Registry: treatment and outcomes in surgical intervention
     Man-Chiu Poon, et al.

1045 Hospital-associated venous thromboembolism in pediatrics: a systematic review and meta-analysis of risk factors and risk-assessment models
     Arash Mahajerin, et al.
Myeloid Malignancies
1051 BRCC3 mutations in myeloid neoplasms
Dayong Huang, et al.

Myeloproliferative Disorders
1058 Ruxolitinib in combination with lenalidomide as therapy for patients with myelofibrosis
Naval Daver, et al.

Acute Myeloid Leukemia
1064 Transcription and methylation analyses of preleukemic promyelocytes indicate a dual role for PML/RARA in leukemia initiation
Coline Gaillard, et al.

Chronic Lymphocytic Leukemia
1076 Targeting the Ataxia Telangiectasia Mutated-null phenotype in chronic lymphocytic leukemia with pro-oxidants
Angelo Agathanggelou, et al.

T-cell Lymphoproliferative Disorders
1086 CD3 CD4+ lymphoid variant of hypereosinophilic syndrome: nodal and extranodal histopathological and immunophenotypic features of a peripheral indolent clonal T-cell lymphoproliferative disorder
Guillaume Lefèvre, et al.

Plasma Cell Disorders
1096 Bendamustine, bortezomib and prednisone for the treatment of patients with newly diagnosed multiple myeloma: results of a prospective phase 2 Spanish/PETHEMA trial
María-Victoria Mateos, et al.

Letters to the Editor
Letters are available online only at www.haematologica.org/content/100/8.toc

e292 Erythropoiesis is not equally suppressed in transfused males and females with β-thalassemia major: are there clinical implications? Greg Happgood, et al.
http://www.haematologica.org/content/100/8/e292

e295 Statin use and bleeding risk during vitamin K antagonist treatment for venous thromboembolism: a multicenter retrospective cohort study
Nicoletta Riva, et al.
http://www.haematologica.org/content/100/8/e295

e299 Imatinib-treated chronic myeloid leukemia patients with discordant response between cytogenetic and molecular tests at 3 and 6 month time-points have a reduced probability of subsequent optimal response
Massimiliano Bonifacio, et al.
http://www.haematologica.org/content/100/8/e299

e302 Resistance to ABT-199 induced by microenvironmental signals in chronic lymphocytic leukemia can be counteracted by CD20 antibodies or kinase inhibitors
Rachel Thijssen, et al.
http://www.haematologica.org/content/100/8/e302

e307 B-cell receptor usage correlates with the sensitivity to CD40 stimulation and the occurrence of CD4- T-cell clonality in chronic lymphocytic leukemia
Nadja Zaborsky, et al.
http://www.haematologica.org/content/100/8/e307
e311 Ofatumumab monotherapy in fludarabine-refractory chronic lymphocytic leukemia: final results from a pivotal study
Anders Österborg, et al.
http://www.haematologica.org/content/100/8/e311

e315 Proteasome inhibitors block Ikaros degradation by lenalidomide in multiple myeloma
Chang-Xin Shi, et al.
http://www.haematologica.org/content/100/8/e315

e318 Characterization of CMV-specific CD4+ T-cell reconstitution following stem cell transplantation through the use of HLA class II-peptide tetramers identifies patients at high risk of recurrent CMV reactivation
Mohammad Raeiszadeh, et al.
http://www.haematologica.org/content/100/8/e318

e323 Simvastatin improves hematopoietic stem cell engraftment by preventing irradiation-induced marrow adipogenesis and radio-protecting the niche cells
Manmohan S. Bajaj, et al.
http://www.haematologica.org/content/100/8/e323

e328 Impact of maintenance therapy on subsequent treatment in patients with newly diagnosed multiple myeloma: use of “progression-free survival 2” as a clinical trial end-point
Meletios A. Dimopoulos, et al.
http://www.haematologica.org/content/100/8/e328

e331 ADAM17 and CD56lowCD16low NK cells
Rizwan Romee, et al.
http://www.haematologica.org/content/100/8/e331

e332 Response to comment on Multifunctional human CD56~CD16~ NK cells are the prominent subset in bone marrow of both pediatric healthy donors and leukemic patients
Helena Stabile, et al.
http://www.haematologica.org/content/100/8/e332